The invention provides novel heterocyclic compounds having the general formula (I) or (II), and pharmaceutically acceptable salts thereof, wherein the variables are as described herein.

##STR00001##

Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds for the treatment or prevention of acute neurological disorders, chronic neurological disorders and/or cognitive disorders.

The present invention relates to delayed release pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for the preparation and use of the compositions.

The present invention relates to prepare pharmaceutical compositions comprising pimavanserin or a pharmaceutically acceptable salt thereof, processes for manufacturing said pharmaceutical compositions comprising pimavanserin or a pharmaceutically acceptable salt thereof. Also pharmaceutical compositions comprising pimavanserin or a pharmaceutically acceptable salt thereof for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

The disclosure relates to a dosage form comprising a hard gelatin or a HPMC capsule having a granule composition comprising tafamidis or its pharmaceutically acceptable salt particularly tafamidis meglumine or solid-state forms or polymorphic forms of tafamidis particularly a solid-state form comprising tafamidis and fumaric acid. The disclosure also relates to a tablet comprising tafamidis or its pharmaceutically acceptable salt particularly tafamidis meglumine or solid-state forms or polymorphic forms of tafamidis particularly a solid-state form comprising tafamidis and fumaric acid. The solid dosage forms disclosed herein do not form a rigid gel upon contacting with water or buffer solution in dissolution specifically pH 6.8 phosphate buffer and the compositions disclosed herein are indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.

The present invention relates to a process for the production of a microcapsule comprising an active ingredient or inactive precursor thereof, as well as a microcapsule obtainable thereby. The process involves the use of a surface-reacted calcium carbonate as a template for encapsulating the active ingredient or inactive precursor thereof. The active ingredient or inactive precursor thereof is loaded onto the surface-reacted calcium carbonate and subsequently encased by a multilayer shell comprising at least two complementary layers using layer-by-layer assembly. Further aspects of the invention relate to the use of a surface-reacted calcium carbonate as a template for encapsulating the active ingredient or inactive precursor thereof, a product comprising said microcapsule, as well as the use of said microcapsule.

The present disclosure relates to pharmaceutical composition comprising 1) an amorphous solid dispersion comprising pralsetinib, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable hydrophilic polymer; and 2) an effervescent couple; and crystalline forms of pralsetinib and pralsetinib hydrochloride salt, which are useful as a RET selective inhibitors. The present disclosure also provides pharmaceutically acceptable compositions comprising the crystalline forms and methods of using said compositions in the treatment of various disorders.

Provided herein are compositions for the ingestible administration of lisinopril. In some embodiments the compositions comprise lisinopril and silicon. In some embodiments, the compositions comprise lisinopril, silicon, magnesium metal, and copper (I) chloride. Also provided herein are apparatuses comprising the compositions provided herein. Also provided herein are methods for using the compositions and apparatuses provided herein.

A drug and layered silicate composite is provided. The drug and layered silicate contains layered silicate powders and a drug compound bound to between layers of the silicate powders, wherein the drug compound is present in an amorphous state in the composite. Using such a composite may significantly improve absorption and bioavailability of a sorafenib compound.

An object of the present invention is to provide a method for stabilizing a substance DFP-11207 sensitive to humidity and unstable at high humidity, and a stabilized preparation thereof, and more specifically, provide a capsule preparation for treating cancer, containing DFP-11207 or a pharmaceutically acceptable salt thereof and a hygroscopic agent.

A solid pharmaceutical composition, with no narcotic action, for the oral administration of ademetionine and cannabidiol, to the method for preparing it, and to the pharmaceutical, nutraceutical or veterinary formulations containing it.